Ann Dermatol.  2019 Aug;31(Suppl):S27-S28. 10.5021/ad.2019.31.S.S27.

Perioral Dermatitis Successfully Treated with Topical Ivermectin

• Charnowski S
• Wollenberg A
• Reinholz M

• KMID: 2456668
• DOI: http://doi.org/10.5021/ad.2019.31.S.S27

Abstract

No abstract available.

MeSH Terms

Dermatitis, Perioral*
Ivermectin*
Ivermectin

Figure

• 

  Fig. 1 (A) Patient with typical symptoms of perioral dermatitis. (B) Patient after 4 weeks of topical treatment with ivermectin cream (10 mg/g) once daily with considerably improved skin. (C) Patient after 12 weeks of topical treatment with ivermectin cream (10 mg/g) once daily with no longer detectable rash.

Reference

1. Marks R, Black MM. Perioral dermatitis. A histopathologic study of 26 cases. Br J Dermatol. 1971; 84:242–247.

2. Nguyen V, Eichenfield LF. Periorificial dermatitis in children and adolescents. J Am Acad Dermatol. 2006; 55:781–785.

3. Wollenberg A, Bieber T, Dirschka T, Luger T, Meurer M, Proksch E, et al. Perioral dermatitis. J Dtsch Dermatol Ges. 2011; 9:422–427.

4. Dirschka T, Tronnier H, Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004; 150:1136–1141.

5. Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016; 15:325–332.